SB450 (2022) Detail

Relative to the prescription drug affordability board.


SB 450  - AS INTRODUCED

 

 

2022 SESSION

22-3071

05/11

 

SENATE BILL 450

 

AN ACT relative to the prescription drug affordability board.

 

SPONSORS: Sen. Sherman, Dist 24; Sen. Rosenwald, Dist 13; Sen. Watters, Dist 4; Sen. Carson, Dist 14; Sen. Gannon, Dist 23; Sen. Perkins Kwoka, Dist 21; Sen. Prentiss, Dist 5; Rep. Merchant, Sull. 4; Rep. Marsh, Carr. 8; Rep. Murphy, Graf. 12

 

COMMITTEE: Health and Human Services

 

-----------------------------------------------------------------

 

ANALYSIS

 

This bill expands the ability of alternates to sit on the New Hampshire prescription drug affordability board, revises the board's conflict of interest requirements and certain fee assessments.

 

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

 

Explanation: Matter added to current law appears in bold italics.

Matter removed from current law appears [in brackets and struckthrough.]

Matter which is either (a) all new or (b) repealed and reenacted appears in regular type.

22-3071

05/11

 

STATE OF NEW HAMPSHIRE

 

In the Year of Our Lord Two Thousand Twenty Two

 

AN ACT relative to the prescription drug affordability board.

 

Be it Enacted by the Senate and House of Representatives in General Court convened:

 

1  New Hampshire Prescription Drug Affordability Board; Alternates.  Amend RSA 126-BB:2, I to read as follows:

I.  The board shall consist of 5 members with expertise in health care economics or clinical medicine, who shall not be, or be directly related to, anyone affiliated with, employed by, or representing the interests of a public payor, pharmaceutical or pharmacy company, pharmacy benefits management company, or health insurance provider and who have completed a conflict of interest statement.  They shall be appointed as follows:

(a)  Two members by the president of the senate.  The president of the senate shall also appoint one alternate board member who will participate in deliberations of the board in the event a member appointed by the president of the senate elects to be recused as provided in RSA 126-BB:3, or pursuant to subparagraph (d).

(b)  Two members by the speaker of the house of representatives.  The speaker of the house of representatives shall also appoint one alternate board member who will participate in deliberations of the board in the event a member appointed by the speaker of the house of representatives elects to be recused as provided in RSA 126-BB:3, or pursuant to subparagraph (d).

(c)  One member by the governor.  The governor shall also appoint one alternate board member who shall participate in deliberations of the board in the event the member appointed by the governor elects to be recused as provided in RSA 126-BB:3, or pursuant to subparagraph (d).

(d)  Any alternate may serve in the place of any absent member at the discretion of the chair for the purpose of meeting the quorum in RSA 126-BB:2, III.

2  New Hampshire Prescription Drug Affordability Board; Conflicts of Interest.  Amend RSA 126-BB:3,II(e) and (f) to read as follows:

(e)  The board, the advisory council, a member of the board or staff, or [a contractor of the board may not accept gifts, bequests, or donations of services or property that suggest a conflict of interest or have the appearance of creating bias in the work of the board or advisory council] any individual associated with the board whom the board deems appropriate by a majority vote of the board shall comply with the provisions of RSA 15-B.

(f)  A member of the advisory council [who accepts a gift, bequest, or donation of services or property that suggests a conflict of interest or has the appearance of creating bias in the work of the advisory council shall disclose the gift, bequest, or donation publicly] shall comply with the provisions of RSA 15-B.

3  Funding; Assessment of Fees.  Amend RSA 126-BB:8, I(e) to read as follows:

(e)  Annual assessments of not less than $500 assessed by the board against prescription drug manufacturers, wholesale drug distributors, and pharmacy benefits managers, including those that process and pay claims on the basis of claims processed or paid for each plan sponsor.

4  Repeal.  RSA 126-BB:8, I(c)(4), relative to annual assessment of pharmacy benefits managers, is repealed.

5  Effective Date.  This act shall take effect 60 days after its passage.

Links

SB450 at GenCourtMobile

Action Dates

Date Body Type
Jan. 20, 2022 Senate Hearing

Bill Text Revisions

SB450 Revision: 34621 Date: Dec. 30, 2021, 2:30 p.m.

Docket


Jan. 13, 2022: Hearing: 01/20/2022, Room 101, LOB, 11:00 am; SC 3


Dec. 30, 2021: To Be Introduced 01/05/2022 and Referred to Health and Human Services; SJ 1